Stocks · News reference
Envoy Medical reported improved 12-month hearing results for its Acclaim cochlear implant as its pivotal trial advances toward FDA filing.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Top Wall Street analysts changed outlook on top names. Baird raised PSN target, BTIG cut WMT target, HSBC raised TX target, Rothschild upgraded EFX, HC Wainwright lowered COCH target, BTIG cut MDXH target, Baird raised ROST target.
HC Wainwright & Co. analyst Yi Chen maintains Envoy Medical (NASDAQ:COCH) with a Buy and lowers the price target from $2.5 to $2.
-SEC Filing
Envoy Medical (NASDAQ:COCH) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 78.13 percent increase over losses of $(0.32) per share from the